Roivant Sciences (ROIV) Operating Expenses (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Operating Expenses came in at $936.0 million in Q4 2025, up 10.1% YoY from $850.2 million in Q4 2024, and up 204.11% on a QoQ basis from $307.8 million in Q3 2025.
Roivant Sciences (ROIV) Operating Expenses (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Operating Expenses data on file, last reported at $936.0 million in Q4 2025.
- Quarterly Operating Expenses rose 10.1% year-over-year to $936.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 8.04% YoY) and the FY2026 annual result came in at $1.3 billion, up 13.2% from the prior year.
- Operating Expenses rose to $936.0 million in Q4 2025, from $307.8 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $1.1 billion in Q4 2021 to a low of $162.1 million in Q2 2021.
- A 5-year average of $511.9 million and a median of $307.8 million in 2025 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2021 — Operating Expenses jumped 342.42% — and 2022, when it slumped 58.01%.
- Tracing ROIV's Operating Expenses over 5 years: stood at $1.1 billion in 2021, then dropped by 13.78% to $975.1 million in 2022, then plunged by 31.47% to $668.2 million in 2023, then grew by 27.23% to $850.2 million in 2024, then rose by 10.1% to $936.0 million in 2025.
- The last three Operating Expenses figures came in at $936.0 million (Q4 2025), $307.8 million (Q3 2025), and $287.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 367.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 367.83 Mn |
| Dec 31, 2025 | 936.05 Mn |
| Sep 30, 2025 | 307.80 Mn |
| Jun 30, 2025 | 287.09 Mn |
| Dec 31, 2024 | 850.20 Mn |
| Sep 30, 2024 | 346.19 Mn |
| Jun 30, 2024 | 220.61 Mn |
| Dec 31, 2023 | 668.24 Mn |
| Sep 30, 2023 | 217.54 Mn |
| Jun 30, 2023 | 298.04 Mn |
| Dec 31, 2022 | 975.06 Mn |
| Sep 30, 2022 | 293.30 Mn |
| Jun 30, 2022 | 286.63 Mn |
| Dec 31, 2021 | 1.13 Bn |
| Sep 30, 2021 | 698.42 Mn |
| Jun 30, 2021 | 162.12 Mn |
| Dec 31, 2020 | 264.82 Mn |
| Sep 30, 2020 | 157.86 Mn |
| Jun 30, 2020 | 116.03 Mn |